Patients should avoid food allergens when taking the drug, according to the FDA. Finally, the biosimilar agent can be used for patients with chronic spontaneous urticaria — ongoing unexplained ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

India should focus on building AI platforms and agents rather than foundational models, leveraging existing technologies to ...

Alvotech, a biotech firm focused on biosimilar medicine development ... employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

Kedaara Capital and TA Associates are in talks to acquire a significant minority stake in Sagent Pharma, valued at $500-600 ...

The new 'living' guideline marks a major shift away from the traditional step-up approach, recommending early use of advanced therapies such as biologics and small molecules after 5-aminosalicylic ...

Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

Two biosimilars, to Humira® (adalimumab ... employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...